title: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.
authors.affiliation: UCL Cancer Institute, University College of London, London, United Kingdom.
authors.forename: Francesca
authors.initials: F
authors.lastname: Vena
authors.affiliation: UCL Cancer Institute, University College of London, London, United Kingdom.
authors.forename: John A
authors.initials: JA
authors.lastname: Hartley
authors.affiliation: UCL Cancer Institute, University College of London, London, United Kingdom. d.hochhauser@ucl.ac.uk.
authors.forename: Daniel
authors.initials: D
authors.lastname: Hochhauser
mesh_terms: D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D000093542:Gemcitabine
chemical_list: C550600:N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide; D047428:Protein Kinase Inhibitors; D003841:Deoxycytidine; D009536:Niacinamide; D000093542:Gemcitabine